DrugPatentWatch Database Preview
Email this page to a colleagueSee Plans and Pricing
« Back to Dashboard
Gemcabene is an investigational drug.
There have been 12 clinical trials for Gemcabene. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2016.
The most common disease conditions in clinical trials are Hypercholesterolemia, Hypertriglyceridemia, and Non-alcoholic Fatty Liver Disease. The leading clinical trial sponsors are Gemphire Therapeutics, Inc., Elif Oral, and Emory University.
There are one hundred and eighteen US patents protecting this investigational drug and two international patents.
Recent Clinical Trials for Gemcabene
|Gemcabene for the Treatment of Pediatric NAFLD||Gemphire Therapeutics, Inc.||Phase 2|
|Gemcabene for the Treatment of Pediatric NAFLD||Emory University||Phase 2|
|Study of Gemcabene in Adults With FPLD||Elif Oral||Phase 1/Phase 2|
Top disease conditions for Gemcabene
Top clinical trial sponsors for Gemcabene
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Gemcabene||Start Trial||Methods of reducing risk of cardiovascular disease||Gemphire Therapeutics Inc. (Livonia, MI)||Start Trial|
|Gemcabene||Start Trial||Carboxyalkylethers, formulations, and treatment of vascular diseases||Warner-Lambert Company (Morris Plains, NJ)||Start Trial|
|Gemcabene||Start Trial||Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals||Aventis Pharma Deutschland GmbH (Frankfurt am Main, DE)||Start Trial|
|Gemcabene||Start Trial||Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals||Aventis Pharma Deutschland GmbH (Frankfurt Am Main, DE)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|